psalexa
logo

Cushing’s Syndrome Therapeutics - Pipeline Analysis 2017

Cushing’s Syndrome Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS10981
Available Format:
Pages: 70

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Cushing’s syndrome is a disease characterized by excess production of cortisol hormone in the blood. It is a severe disease that can be long term and may be life threatening because of the various complications associated with the it such as, diabetes, high blood pressure and mental problems. The common symptoms of the disease include weight gain, roundish face, easy bruising, excessive growth of coarse hair on the face, weakening of the muscles and bones, growth of fat above the collar bone and the back of the neck. The disease is usually caused by a tumor of the pituitary gland (a gland which is situated in the hypothalamus region of the brain) that produces excess amounts of adrenocorticotropic hormone (ACTH), which in turn stimulates the production of excess cortisol from the adrenal glands, which are situated above the kidneys.

 
CUSHING’S SYNDROME THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Cushings Syndrome Therapeutics

Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome. Further companies such as Millendo Therapeutics, Inc., and Corcept Therapeutics Incorporated, have one drug candidate each, in the Phase II stage of development for the treatment of Cushing’s syndrome. Angion Biomedica Corp is in the process of discovery of ANG-3563 for the treatment of Cushing syndrome.

Pipeline Analysis

As of November 2017, the Cushing’s syndrome therapeutics pipeline comprises of 13 drug candidates in different stages of development.

Competitive Landscape

Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry